Ann: Investor Presentation - $66m Capital Raise, page-60

Just going by reaction to price sensitive releases
in the past, and the fact that 008 is such a small
study. Same with canine study. Don’t think it
will be enough to impress instos or FDA. I think
small investors will embrace it, but is that enough
to sustain the inevitable spike. IMO we will need
results from the larger trials to have sustained
growth in the share price. Management seems
to have put a partnership off the agenda (at least
for the time being) for OA.

Fast track designation should be helpful, but
remember, Novartis has fast track for their)
LNA043 P3 trial (claiming DMOAD).